1. Home
  2. IXHL vs PDSB Comparison

IXHL vs PDSB Comparison

Compare IXHL & PDSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Incannex Healthcare Inc.

IXHL

Incannex Healthcare Inc.

N/A

Current Price

$1.96

Market Cap

35.4M

Sector

N/A

ML Signal

N/A

Logo PDS Biotechnology Corporation

PDSB

PDS Biotechnology Corporation

N/A

Current Price

$1.02

Market Cap

42.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
IXHL
PDSB
Founded
2001
2005
Country
Australia
United States
Employees
N/A
10
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
35.4M
42.4M
IPO Year
2024
2015

Fundamental Metrics

Financial Performance
Metric
IXHL
PDSB
Price
$1.96
$1.02
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
★ $4.50
AVG Volume (30 Days)
69.0K
★ 6.7M
Earning Date
11-24-2026
11-24-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 28.16
EPS
N/A
★ N/A
Revenue
★ $12,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.16
$0.20
52 Week High
$6.39
$1.79

Technical Indicators

Market Signals
Indicator
IXHL
PDSB
Relative Strength Index (RSI) 21.19 44.01
Support Level $0.20 $0.92
Resistance Level $3.82 $1.00
Average True Range (ATR) 0.19 0.17
MACD -0.04 -0.06
Stochastic Oscillator 6.02 6.07

Price Performance

Historical Comparison
IXHL
PDSB

About IXHL Incannex Healthcare Inc.

Incannex Healthcare Inc is a clinical-stage biopharmaceutical development company dedicated to developing inventive medicines for patients living with serious chronic diseases and unmet needs. The Company's drug candidates include IHL-42X for the treatment of obstructive sleep apnea (OSA) and PSX-001, the Company's psilocybin treatment in combination with psychological therapy in development to treat patients with generalized anxiety disorder (GAD). The Company also has a drug candidate, IHL-675A, for the treatment of rheumatoid arthritis. Each of these programs target conditions that currently have limited, inadequate, or no approved pharmaceutical treatment options. The Company continues to evaluate strategies for IHL-675A when and as resources permit.

About PDSB PDS Biotechnology Corporation

PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.

Share on Social Networks: